Production (Stage)
Black Diamond Therapeutics, Inc.
BDTX
$1.99
-$0.06-2.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.61% | -9.54% | -6.01% | 9.16% | -1.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.54% | -12.29% | -6.97% | 1.96% | -4.02% |
| Operating Income | 98.76% | 12.29% | 6.97% | -1.96% | 4.02% |
| Income Before Tax | 106.38% | 15.48% | 13.09% | 2.67% | 7.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 106.38% | 15.48% | 13.09% | 2.67% | 7.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 106.38% | 15.48% | 13.09% | 2.67% | 7.79% |
| EBIT | 98.76% | 12.29% | 6.97% | -1.96% | 4.02% |
| EBITDA | 99.16% | 12.24% | 6.86% | -2.11% | 3.92% |
| EPS Basic | 104.65% | 33.97% | 35.89% | 32.20% | 28.38% |
| Normalized Basic EPS | 106.39% | 35.50% | 36.00% | 32.39% | 28.65% |
| EPS Diluted | 103.60% | 33.97% | 35.89% | 32.20% | 28.38% |
| Normalized Diluted EPS | 105.39% | 35.50% | 36.00% | 32.39% | 28.65% |
| Average Basic Shares Outstanding | 17.83% | 25.34% | 34.16% | 43.78% | 31.19% |
| Average Diluted Shares Outstanding | 18.35% | 25.34% | 34.16% | 43.78% | 31.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |